{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:56:15Z","timestamp":1781697375842,"version":"3.54.5"},"reference-count":45,"publisher":"Becaris Publishing Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Dry eye disease (DED) is a chronic, multifactorial condition arising through loss of tear film and ocular surface homeostasis. Treatment aims to restore natural tear production and normalize ocular surface homeostasis. Several prescription medications are available in the US that increase tear production in patients with DED. In the absence of head-to-head trials, this study employed a matching-adjusted indirect comparison (MAIC) approach to estimate the comparative tear production efficacy of acoltremon 0.003% and cyclosporine 0.05% for the treatment of DED.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    MAICs were conducted for the key outcome of categorized Schirmer test score (STS), where higher values indicate greater tear production. Patient data were available for acoltremon 0.003% (from COMET-2 and COMET-3 trials) and summary level data for cyclosporine 0.05%. Populations were matched on clinically relevant variables including age, race, sex and anesthetized categorized STS. The primary analysis compared mean change from baseline (CFB) categorized STS at day 90. An exploratory analysis investigated earlier onset of tear production (day 14) attributed to acoltremon 0.003% compared with the earliest available data (day 90) for cyclosporine 0.05%.\n                    <jats:bold>Results:<\/jats:bold>\n                    After all adjustments, a greater mean CFB categorized STS was observed for acoltremon 0.003% compared with cyclosporine 0.05% (mean difference [MD]: 1.62 categories, 95% CI: 1.42\u20131.83, p\u00a0&lt;\u00a00.001) at day 90. The exploratory analysis also demonstrated a greater mean CFB categorized STS for day 14 acoltremon 0.003% compared with day 90 cyclosporine 0.05% (MD: 1.62 categories, 95% CI: 1.42\u20131.82, p\u00a0&lt;\u00a00.001).\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Our findings suggest that acoltremon 0.003% may provide a greater increase in tear production relative to cyclosporine 0,05% at day 90, with exploratory findings suggesting similar results at day 14. As this was an unanchored MAIC, results may be influenced by residual confounding from unmeasured differences between trials.\n                  <\/jats:p>","DOI":"10.57264\/cer-2026-0032","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:06:14Z","timestamp":1778763974000},"source":"Crossref","is-referenced-by-count":0,"title":["Matching-adjusted indirect comparison of acoltremon ophthalmic solution 0.003% and cyclosporine 0.05% ophthalmic emulsion for increased tear production in patients with dry eye disease"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9341-3482","authenticated-orcid":false,"given":"Stephen","family":"Pflugfelder","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6522-2199","authenticated-orcid":false,"given":"Tony","family":"Okoro","sequence":"additional","affiliation":[{"name":"Alcon, Fort Worth, TX 76134-2001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5678-1227","authenticated-orcid":false,"given":"Margaret","family":"Ainslie-Garcia","sequence":"additional","affiliation":[{"name":"EVERSANA, Victoria, BC, V8W 2E1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9829-7791","authenticated-orcid":false,"given":"Anja","family":"Haltner","sequence":"additional","affiliation":[{"name":"EVERSANA, New York, NY 10018, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6314-5908","authenticated-orcid":false,"given":"Emily K","family":"Prentiss","sequence":"additional","affiliation":[{"name":"EVERSANA, Chicago, IL 60601, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1850-9855","authenticated-orcid":false,"given":"Elizabeth M","family":"Salvo-Halloran","sequence":"additional","affiliation":[{"name":"EVERSANA, Victoria, BC, V8W 2E1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4548-8374","authenticated-orcid":false,"given":"Nikethana","family":"Srikanth","sequence":"additional","affiliation":[{"name":"EVERSANA, Victoria, BC, V8W 2E1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8909-6843","authenticated-orcid":false,"given":"Michelle","family":"Senchyna","sequence":"additional","affiliation":[{"name":"Alcon, Fort Worth, TX 76134-2001, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esen K","family":"Akpek","sequence":"additional","affiliation":[{"name":"Foster Center for Ocular Immunology and Inflammation, Duke University School of Medicine, Durham, NC 27705, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_10_3_2","unstructured":"MarketScope. 2024 dry eye products market report: a global analysis for 2023 to 2029. (2024). https:\/\/www.market-scope.com\/pages\/reports\/481\/2024-dry-eye-products-market-report-global-analysis-for-2023-to-2029-december-2024"},{"key":"e_1_3_10_4_2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ajo.2025.05.033","article-title":"TFOS DEWS III: diagnostic methodology","volume":"279","author":"Wolffsohn JS","year":"2025","unstructured":"Wolffsohn JS, Ben\u00edtez-Del-Castillo JM, Loya-Garcia D TFOS DEWS III: diagnostic methodology. Am. J. Ophthalmol. 279, 387\u2013450 (2025).","journal-title":"Am. J. Ophthalmol."},{"issue":"7","key":"e_1_3_10_5_2","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1167\/iovs.16-19419","article-title":"Impact of dry eye disease on work productivity, and patients' satisfaction with over-the-counter dry eye treatments","volume":"57","author":"Nichols KK","year":"2016","unstructured":"Nichols KK, Bacharach J, Holland E Impact of dry eye disease on work productivity, and patients' satisfaction with over-the-counter dry eye treatments. Invest. Ophthalmol. Vis. Sci. 57(7), 2975\u20132982 (2016).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"e_1_3_10_6_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ajo.2019.01.026","article-title":"Estimated prevalence and incidence of dry eye disease based on coding analysis of a large, all-age united states health care system","volume":"202","author":"Dana R","year":"2019","unstructured":"Dana R, Bradley JL, Guerin A Estimated prevalence and incidence of dry eye disease based on coding analysis of a large, all-age united states health care system. Am. J. Ophthalmol. 202, 47\u201354 (2019).","journal-title":"Am. J. Ophthalmol."},{"issue":"2","key":"e_1_3_10_7_2","first-page":"1611","article-title":"The negative effects of dry eye disease on quality of life and visual function","volume":"50","author":"Guo OL","year":"2020","unstructured":"Guo OL, Akpek E. The negative effects of dry eye disease on quality of life and visual function. Turk. J. Med. Sci. 50(Si\u20132), 1611\u20131615 (2020).","journal-title":"Turk. J. Med. Sci."},{"key":"e_1_3_10_8_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ajo.2019.10.009","article-title":"Sustained gazing causes measurable decline in visual function of patients with dry eye","volume":"210","author":"Akpek EK","year":"2020","unstructured":"Akpek EK, Karakus S, Ramulu PY, Mathews PM. Sustained gazing causes measurable decline in visual function of patients with dry eye. Am. J. Ophthalmol. 210, 107\u2013115 (2020).","journal-title":"Am. J. Ophthalmol."},{"issue":"1","key":"e_1_3_10_9_2","doi-asserted-by":"crossref","first-page":"e000709","DOI":"10.1136\/bmjophth-2021-000709","article-title":"Economic burden and loss of quality of life from dry eye disease in Canada","volume":"6","author":"Chan C","year":"2021","unstructured":"Chan C, Ziai S, Myageri V, Burns JG, Prokopich CL. Economic burden and loss of quality of life from dry eye disease in Canada. BMJ Open Ophthalmol. 6(1), e000709 (2021).","journal-title":"BMJ Open Ophthalmol."},{"issue":"4","key":"e_1_3_10_10_2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/ICO.0b013e3181f7f363","article-title":"The economic burden of dry eye disease in the United States: a decision tree analysis","volume":"30","author":"Yu J","year":"2011","unstructured":"Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea 30(4), 379\u2013387 (2011).","journal-title":"Cornea"},{"issue":"10","key":"e_1_3_10_11_2","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.ophtha.2020.04.037","article-title":"Ophthalmic medication expenditures and out-of-pocket spending: an analysis of United States prescriptions from 2007 through 2016","volume":"127","author":"Chen E","year":"2020","unstructured":"Chen E, Kombo N, Teng CC, Mruthyunjaya P, Nwanyanwu K, Parikh R. Ophthalmic medication expenditures and out-of-pocket spending: an analysis of United States prescriptions from 2007 through 2016. Ophthalmology 127(10), 1292\u20131302 (2020).","journal-title":"Ophthalmology"},{"issue":"6","key":"e_1_3_10_12_2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/ICO.0000000000003567","article-title":"Long-term safety and efficacy of a water-free cyclosporine 0.1% ophthalmic solution for treatment of dry eye disease: ESSENCE-2 OLE","volume":"44","author":"Wirta DL","year":"2025","unstructured":"Wirta DL, Galor A, Aune CA Long-term safety and efficacy of a water-free cyclosporine 0.1% ophthalmic solution for treatment of dry eye disease: ESSENCE-2 OLE. Cornea 44(6), 692\u2013670 (2025).","journal-title":"Cornea"},{"key":"e_1_3_10_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.05.039"},{"issue":"4","key":"e_1_3_10_14_2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5301\/ejo.5000779","article-title":"Efficacy and safety of 0.1% cyclosporine a cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial","volume":"26","author":"Leonardi A","year":"2016","unstructured":"Leonardi A, Van Setten G, Amrane M Efficacy and safety of 0.1% cyclosporine a cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur. J. Ophthalmol. 26(4), 287\u2013296 (2016).","journal-title":"Eur. J. Ophthalmol."},{"key":"e_1_3_10_15_2","first-page":"251584141987036","article-title":"Lifitegrast: a novel drug for patients with dry eye disease","volume":"11","author":"Haber SL","year":"2019","unstructured":"Haber SL, Benson V, Buckway CJ, Gonzales JM, Romanet D, Scholes B. Lifitegrast: a novel drug for patients with dry eye disease. Ther. Adv. Ophthalmol. 11, 2515841419870366 (2019).","journal-title":"Ther. Adv. Ophthalmol."},{"key":"e_1_3_10_16_2","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2147\/OPTH.S226168","article-title":"Real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye","volume":"13","author":"White DE","year":"2019","unstructured":"White DE, Zhao Y, Ogundele A Real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye. Clin. Ophthalmol. 13, 2285\u20132292 (2019).","journal-title":"Clin. Ophthalmol."},{"key":"e_1_3_10_17_2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2147\/OPTH.S233194","article-title":"Treatment satisfaction among patients using anti-inflammatory topical medications for dry eye disease","volume":"14","author":"White DE","year":"2020","unstructured":"White DE, Zhao Y, Jayapalan H, Machiraju P, Periyasamy R, Ogundele A. Treatment satisfaction among patients using anti-inflammatory topical medications for dry eye disease. Clin. Ophthalmol. 14, 875\u2013883 (2020).","journal-title":"Clin. Ophthalmol."},{"key":"e_1_3_10_18_2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2147\/OPTH.S237832","article-title":"Physician satisfaction with anti-inflammatory topical medications for the treatment of dry eye disease","volume":"14","author":"White DE","year":"2020","unstructured":"White DE, Zhao Y, Jayapalan H, Machiraju P, Periyasamy R, Ogundele A. Physician satisfaction with anti-inflammatory topical medications for the treatment of dry eye disease. Clin. Ophthalmol. 14, 931\u2013938 (2020).","journal-title":"Clin. Ophthalmol."},{"issue":"3","key":"e_1_3_10_19_2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40123-019-0188-4","article-title":"Evaluating patient experiences in dry eye disease through social media listening research","volume":"8","author":"Cook N","year":"2019","unstructured":"Cook N, Mullins A, Gautam R Evaluating patient experiences in dry eye disease through social media listening research. Ophthalmol. Ther. 8(3), 407\u2013420 (2019).","journal-title":"Ophthalmol. Ther."},{"key":"e_1_3_10_20_2","volume-title":"American Society of Cataract and Refractive Surgery Annual Meeting","author":"Mbagwu M","year":"2024","unstructured":"Mbagwu M, LaPrise A, Harris J Characterization of discontinuation and switching patterns of dry eye disease medications using linked EHR registry and claims data. Presented at: American Society of Cataract and Refractive Surgery Annual Meeting, Boston, MA, USA (2024). 8 April 2024, Abstract 99117. https:\/\/ascrs.confex.com\/ascrs\/24am\/meetingapp.cgi\/Paper\/99117"},{"issue":"10","key":"e_1_3_10_21_2","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1097\/MS9.0000000000002550","article-title":"Navigating dry eye relief: meibo's approach to controlling tear evaporation","volume":"86","author":"Ahmed B","year":"2024","unstructured":"Ahmed B, Shahzad Y, Urooj W, Siddiqui A, Nisa Mughal ZU, Abbasher Hussien Mohamed Ahmed K. Navigating dry eye relief: meibo's approach to controlling tear evaporation. Ann. Med. Surg. (Lond.) 86(10), 5680\u20135684 (2024).","journal-title":"Ann. Med. Surg. (Lond.)"},{"issue":"14","key":"e_1_3_10_22_2","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s40265-022-01782-4","article-title":"Varenicline solution nasal spray: a review in dry eye disease","volume":"82","author":"Frampton JE","year":"2022","unstructured":"Frampton JE. Varenicline solution nasal spray: a review in dry eye disease. Drugs 82(14), 1481\u20131488 (2022).","journal-title":"Drugs"},{"key":"e_1_3_10_23_2","unstructured":"Alcon. Tryptyr (acoltremon ophthalmic solution) 0.003%. (2025). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/217370s000lbl.pdf"},{"issue":"1","key":"e_1_3_10_24_2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1021\/cn100102c","article-title":"Chemosensory properties of the trigeminal system","volume":"2","author":"Viana F","year":"2011","unstructured":"Viana F. Chemosensory properties of the trigeminal system. ACS Chem. Neurosci. 2(1), 38\u201350 (2011).","journal-title":"ACS Chem. Neurosci."},{"key":"e_1_3_10_25_2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jtos.2022.08.003","article-title":"A randomized, vehicle-controlled, Phase IIb study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1)","volume":"26","author":"Wirta DL","year":"2022","unstructured":"Wirta DL, Senchyna M, Lewis AE A randomized, vehicle-controlled, Phase IIb study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1). Ocul. Surf. 26, 166\u2013173 (2022).","journal-title":"Ocul. Surf."},{"issue":"3","key":"e_1_3_10_26_2","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtos.2017.05.002","article-title":"TFOS DEWS II pain and sensation report","volume":"15","author":"Belmonte C","year":"2017","unstructured":"Belmonte C, Nichols JJ, Cox SM TFOS DEWS II pain and sensation report. Ocul. Surf. 15(3), 404\u2013437 (2017).","journal-title":"Ocul. Surf."},{"key":"e_1_3_10_27_2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jtos.2025.07.003","article-title":"Corneal sensory nerve regulation of tear production through stimulation of transient receptor potential melastatin 8 (TRPM8) channel: a potential new approach for treating dry eye disease","volume":"38","author":"Gallar J","year":"2025","unstructured":"Gallar J, Pflugfelder S, Galor A, Gupta PK, Hamrah P. Corneal sensory nerve regulation of tear production through stimulation of transient receptor potential melastatin 8 (TRPM8) channel: a potential new approach for treating dry eye disease. Ocul. Surf. 38, 142\u2013154 (2025).","journal-title":"Ocul. Surf."},{"issue":"5","key":"e_1_3_10_28_2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ophtha.2025.09.018","article-title":"Acoltremon ophthalmic solution 0.003% for signs and symptoms of dry eye disease: results of Phase III pivotal studies COMET-2 and COMET-3","volume":"133","author":"Pattar GR","year":"2026","unstructured":"Pattar GR, Wirta D, Jerkins G Acoltremon ophthalmic solution 0.003% for signs and symptoms of dry eye disease: results of Phase III pivotal studies COMET-2 and COMET-3. Ophthalmology 133(5), 563\u2013574 (2026).","journal-title":"Ophthalmology"},{"issue":"1","key":"e_1_3_10_29_2","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s12886-024-03565-9","article-title":"Bridging the gap in managing dry eye disease: a consensus report by the Taiwan Society of Cataract and Refractive Surgeons","volume":"24","author":"Sun CC","year":"2024","unstructured":"Sun CC, Hsu SL, Liang CM, Tsai YY, Lin PY. Bridging the gap in managing dry eye disease: a consensus report by the Taiwan Society of Cataract and Refractive Surgeons. BMC Ophthalmol. 24(1), 314 (2024).","journal-title":"BMC Ophthalmol."},{"issue":"21","key":"e_1_3_10_30_2","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.3390\/jcm11216437","article-title":"The management of dry eye disease: proceedings of Italian Dry Eye Consensus Group using the Delphi method","volume":"11","author":"Aragona P","year":"2022","unstructured":"Aragona P, Giannaccare G, Mencucci R The management of dry eye disease: proceedings of Italian Dry Eye Consensus Group using the Delphi method. J. Clin. Med. 11(21), 6437 (2022).","journal-title":"J. Clin. Med."},{"issue":"4","key":"e_1_3_10_31_2","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1016\/j.ophtha.2023.12.041","article-title":"American Academy of Ophthalmology Preferred Practice Pattern Cornea\/External Disease Panel. Dry Eye Syndrome Preferred Practice Pattern\u00ae","volume":"131","author":"Amescua G","year":"2024","unstructured":"Amescua G, Ahmad S, Cheung AY American Academy of Ophthalmology Preferred Practice Pattern Cornea\/External Disease Panel. Dry Eye Syndrome Preferred Practice Pattern\u00ae. Ophthalmology 131(4), P1\u2013P49 (2024).","journal-title":"Ophthalmology"},{"issue":"1","key":"e_1_3_10_32_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.icu.0000512373.81749.b7","article-title":"Dysfunctional tear syndrome: dry eye disease and associated tear film disorders \u2013 new strategies for diagnosis and treatment","volume":"27","author":"Milner MS","year":"2017","unstructured":"Milner MS, Beckman KA, Luchs JI Dysfunctional tear syndrome: dry eye disease and associated tear film disorders \u2013 new strategies for diagnosis and treatment. Curr. Opin. Ophthalmol. 27(Suppl. 1), 3\u201347 (2017).","journal-title":"Curr. Opin. Ophthalmol."},{"issue":"6","key":"e_1_3_10_33_2","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch JE","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 15(6), 940\u2013947 (2012).","journal-title":"Value Health"},{"issue":"4","key":"e_1_3_10_34_2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CSA Phase III Study Group","volume":"107","author":"Sall K","year":"2000","unstructured":"Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CSA Phase III Study Group. Ophthalmology 107(4), 631\u2013639 (2000).","journal-title":"Ophthalmology"},{"key":"e_1_3_10_35_2","unstructured":"NICE. NICE single technology appraisal and highly specialised technologies evaluation: user guide for company evidence submission template. (2024). https:\/\/www.nice.org.uk\/process\/pmg24\/resources\/single-technology-appraisal-and-highly-specialised-technologies-evaluation-user-guide-for-company-evidence-submission-template-pdf-72286715419333"},{"issue":"4","key":"e_1_3_10_36_2","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s40123-023-00720-1","article-title":"Possible strategies to mitigate placebo or vehicle response in dry eye disease trials: a narrative review","volume":"12","author":"Montecchi-Palmer M","year":"2023","unstructured":"Montecchi-Palmer M, Wu M, Rolando M, Lau C, Perez Quinones VL, Dana R. Possible strategies to mitigate placebo or vehicle response in dry eye disease trials: a narrative review. Ophthalmol. Ther. 12(4), 1827\u20131849 (2023).","journal-title":"Ophthalmol. Ther."},{"key":"e_1_3_10_37_2","unstructured":"AbbVie. Restasis (cyclosporine 0.05%). (2025). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/050790s031lbl.pdf"},{"key":"e_1_3_10_38_2","unstructured":"Phillippo D Ades T Dias S Palmer S Abrams KR Welton N. NICE DSU Technical Support Document 18: methods for population-adjusted indirect comparisons in submissions to NICE. NICE Decision SupportUnit. (2016). Accessed 5 May 2026. http:\/\/www.nicedsu.org.uk\/Populationadjusted-ICs-TSD(3026862).html"},{"issue":"2","key":"e_1_3_10_39_2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for population-adjusted indirect comparisons in health technology appraisal","volume":"38","author":"Phillippo DM","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med. Decis. Mak. 38(2), 200\u2013211 (2018).","journal-title":"Med. Decis. Mak."},{"issue":"10","key":"e_1_3_10_40_2","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","article-title":"Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept","volume":"28","author":"Signorovitch JE","year":"2010","unstructured":"Signorovitch JE, Wu EQ, Yu AP Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics 28(10), 935\u2013945 (2010).","journal-title":"Pharmacoeconomics"},{"issue":"25","key":"e_1_3_10_41_2","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin PC","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat. Med. 28(25), 3083\u20133107 (2009).","journal-title":"Stat. Med."},{"issue":"3","key":"e_1_3_10_42_2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig JP","year":"2017","unstructured":"Craig JP, Nichols KK, Akpek EK TFOS DEWS II definition and classification report. Ocul. Surf. 15(3), 276\u2013283 (2017).","journal-title":"Ocul. Surf."},{"issue":"6","key":"e_1_3_10_43_2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/00003226-199811000-00002","article-title":"The pathology of dry eye: the interaction between the ocular surface and lacrimal glands","volume":"17","author":"Stern ME","year":"1998","unstructured":"Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 17(6), 584\u2013589 (1998).","journal-title":"Cornea"},{"key":"e_1_3_10_44_2","doi-asserted-by":"crossref","first-page":"108115","DOI":"10.1016\/j.exer.2020.108115","article-title":"Biological functions of tear film","volume":"197","author":"Pflugfelder SC","year":"2020","unstructured":"Pflugfelder SC, Stern ME. Biological functions of tear film. Exp. Eye Res. 197, 108115 (2020).","journal-title":"Exp. Eye Res."},{"key":"e_1_3_10_45_2","volume-title":"StatPearls","author":"Brott NR","year":"2024","unstructured":"Brott NR, Zeppieri M, Ronquillo Y. Schirmer Test. 2024 Feb 24. In: StatPearls. StatPearls Publishing, FL, USA (2024)."},{"key":"e_1_3_10_46_2","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.2147\/OPTH.S279051","article-title":"A review of the mechanism of action of cyclosporine A: the role of cyclosporine a in dry eye disease and recent formulation developments","volume":"14","author":"Periman LM","year":"2020","unstructured":"Periman LM, Mah FS, Karpecki PM. A review of the mechanism of action of cyclosporine A: the role of cyclosporine a in dry eye disease and recent formulation developments. Clin. Ophthalmol. 14, 4187\u20134200 (2020).","journal-title":"Clin. Ophthalmol."},{"key":"e_1_3_10_47_2","doi-asserted-by":"crossref","first-page":"1700163","DOI":"10.3389\/fopht.2025.1700163","article-title":"Cyclosporine A in the treatment of dry eye disease: a narrative review","volume":"5","author":"Bian X","year":"2025","unstructured":"Bian X, Ma J, Liu Y Cyclosporine A in the treatment of dry eye disease: a narrative review. Front. Ophthalmol. 5, 1700163 (2025).","journal-title":"Front. Ophthalmol."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2026-0032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:19:47Z","timestamp":1781695187000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2026-0032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.57264\/cer-2026-0032"],"URL":"https:\/\/doi.org\/10.57264\/cer-2026-0032","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"e260032"}}